Daiichi Sankyo completes patient enrollment in Phase III edoxaban study for AFib
Thursday, December 2, 2010
By: Daiichi Sankyo Company, Limited

Daiichi Sankyo Company, Limited

Daiichi Sankyo Company, Limited (TSE: 4568) announced today that it has successfully completed patient enrollment for its Phase III ENGAGE AF-TIMI 48 clinical study of edoxaban, a direct, specific, oral Factor Xa inhibitor that is being investigated in two different dosing regimens given once daily, to prevent the occurrence of strokes and systemic embolic events (SEE) in patients with atrial fibrillation (AFib).

An estimated 2.2 million Americans suffer from AFib, and about 90,000 strokes in the U.S. each year are caused by AF. Due to the aging population, the number of patients with AFib worldwide is likely to increase 2.5-fold by the year 2050. 

Read Full Story...